Lineage Cell Therapeutics, Inc. (LCTX)
Stock Price Chart
Key Info
| Market Cap | 128.85M |
| Revenue (ttm) | 3.10M |
| Net Income (ttm) | -59.42M |
| Shares Out | 149.82M |
| EPS (ttm) | -0.37 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
Stock Quote
| Trading Day | Aug 4, 2020 |
| Last Price | $0.860 |
| Previous Close | $0.850 |
| Change ($) | 0.010 |
| Change (%) | 1.18% |
| Day's Open | 0.853 |
| Day's Range | 0.840 - 0.867 |
| Day's Volume | 431,410 |
| 52-Week Range | 0.534 - 1.670 |
More Stats
| Market Cap | 128.85M |
| Enterprise Value | 83.92M |
| Earnings Date (est) | Aug 6, 2020 |
| Ex-Dividend Date | n/a |
| Shares Outstanding | 149.82M |
| Float | 107.50M |
| EPS (basic) | -0.4 |
| EPS (diluted) | -0.37 |
| FCF / Share | -0.19 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
| Payout Ratio | n/a |
| Shares Short | 5.41M |
| Short Ratio | 3.32 |
| Short % of Float | 4.99% |
| Beta | 2.15 |
| PE Ratio | n/a |
| Forward PE | n/a |
| P/FCF Ratio | n/a |
| PS Ratio | 41.55 |
| PB Ratio | 1.19 |
| Revenue | 3.10M |
| Operating Income | -33.55M |
| Net Income | -59.42M |
| Free Cash Flow | -27.86M |
| Net Cash | 44.93M |
| Net Cash / Share | 0.30 |
| Gross Margin | 100.06% |
| Operating Margin | -1,082.01% |
| Profit Margin | -1,916.10% |
| FCF Margin | -898.36% |
| ROA | -12.99% |
| ROE | -44.78% |
| ROIC | -101.90% |
Analyst Summary
Analyst Consensus: Buy
Financial Performance
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 3.52 | 4.99 | 3.46 | 5.92 | 7.04 | 5.24 | 4.43 | 3.92 | 4.43 | 3.71 |
| Revenue Growth | -29.53% | 44.25% | -41.62% | -15.82% | 34.17% | 18.27% | 13.25% | -11.7% | 19.58% | - |
| Gross Profit | 3.10 | 4.69 | 3.29 | 5.57 | 5.93 | 4.41 | 3.64 | 3.48 | 4.35 | 3.68 |
| Operating Income | -38.88 | -41.80 | -38.90 | -58.97 | -65.81 | -50.68 | -55.99 | -25.32 | -18.69 | -9.85 |
| Net Income | -11.71 | -45.99 | -19.98 | 33.57 | -46.99 | -36.41 | -43.88 | -21.43 | -16.52 | -11.18 |
| Shares Outstanding | 146 | 127 | 114 | 97.32 | 79.71 | 66.47 | 54.23 | 49.21 | 47.05 | 40.27 |
| Earnings Per Share | -0.08 | -0.36 | -0.17 | 0.34 | -0.59 | -0.55 | -0.81 | -0.44 | -0.35 | -0.28 |
| Operating Cash Flow | -31.95 | -30.88 | -30.52 | -42.33 | -44.54 | -38.85 | -29.51 | -19.68 | -13.59 | -7.73 |
| Capital Expenditures | -0.36 | -1.42 | -1.13 | -2.53 | -5.33 | -0.69 | -2.25 | -0.40 | -0.96 | -0.21 |
| Free Cash Flow | -32.31 | -32.30 | -31.64 | -44.85 | -49.88 | -39.55 | -31.76 | -20.08 | -14.55 | -7.95 |
| Cash & Equivalents | 54.33 | 30.74 | 38.18 | 22.72 | 42.98 | 29.49 | 5.62 | 4.41 | 22.27 | 33.38 |
| Total Debt | 5.17 | 2.27 | 1.53 | 3.98 | 5.10 | 0.53 | - | - | - | - |
| Net Cash / Debt | 49.16 | 28.48 | 36.64 | 18.73 | 37.88 | 28.96 | 5.62 | 4.41 | 22.27 | 33.38 |
| Assets | 125 | 102 | 173 | 143 | 94.66 | 74.90 | 57.73 | 29.75 | 45.83 | 53.27 |
| Liabilities | 14.23 | 9.41 | 8.98 | 12.06 | 18.21 | 12.18 | 15.47 | 5.45 | 4.37 | 3.85 |
| Book Value | 113 | 93.84 | 163 | 118 | 25.82 | 36.46 | 14.80 | 9.58 | 28.65 | 38.17 |
Company Profile
Company Details
| Full Name | Lineage Cell Therapeutics, Inc. |
| Country | United States |
| Employees | 50 |
| CEO | Brian M. Culley |
Stock Information
| Ticker Symbol | LCTX |
| Stock Exchange | NYSE American |
| Sector | Healthcare |
| Industry | Biotechnology |
| Unique Identifier | NYSEAMERICAN: LCTX |
Description
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing therapies for the treatment of degenerative diseases in the United States and internationally. The company's lead product candidates include OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa multicenter trial for the treatment of the dry age-related macular degeneration; OPC1, an oligodendrocyte progenitor cell therapy that is in Phase I/IIa multicenter clinical trial for the treatment of acute spinal cord injuries; and VAC2, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer. It also develops Renevia, a facial aesthetics product that is in pivotal clinical trial for the treatment of HIV-associated facial lipoatrophy; ReGlyde, a HyStem product in preclinical development as a device for viscosupplementation, and as a platform for intraarticular drug delivery in osteoarthritis; and Premvia, a Hystem Hydrogel product, as well as develop bone grafting products for the orthopedic diseases and injuries. In addition, it markets GeneCards, a human gene database; MalaCards, a human disease database; and Hextend, a plasma volume expander used to treat or prevent hypovolemia, including albumin, generic 6% hetastarch solutions, and crystalloid solutions, as well as undertakes various research programs for vision restoration and Demyelination. Lineage Cell Therapeutics, Inc. has a collaboration with Orbit Biomedical, Ltd. The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019. Lineage Cell Therapeutics, Inc. was founded in 1990 and is headquartered in Carlsbad, California.